Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132858 · ClinicalTrials.gov registry record
Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation
A clinical trial, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- 43
- Enrollment target
NCT02132858 is a clinical trial that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 43 participants.
The verdict
NCT02132858 has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
This research trial studies genetic mutations in blood and tissue samples to see if they can be used to predict treatment response in patients with locally advanced rectal cancer undergoing chemoradiation. Studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about genetic mutations or changes that occur in deoxyribonucleic acid (DNA) and help doctors understand how patients respond to treatment.
Interventions
- OTHER laboratory biomarker analysis
- OTHER cytology specimen collection procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-07 |
| Est. Completion | 2022-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02132858
The ClinicalTrials.gov registry entry for NCT02132858 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT02132858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02132858 about?
NCT02132858 is a clinical study titled "Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation". This research trial studies genetic mutations in blood and tissue samples to see if they can be used to predict treatment response in patients with locally advanced rectal cancer undergoing chemoradiation. Studying samples of blood and tumor tissue in the laboratory from patients with cancer may hel...
What is the current status of trial NCT02132858?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2014-07. Estimated completion is 2022-10.
What interventions are being tested in trial NCT02132858?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cytology specimen collection procedure (OTHER).
Who is sponsoring clinical trial NCT02132858?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.